AUTHORS
Anand Ashwin Patel, MD, Rafael Madero-Marroquin, MD2, Michael W. Drazer, MD, PhD3, Abdulraheem Yacoub, MD4, Ghaith Abu-Zeinah I, MD5, Michael J. Thirman, MD6, Ashwin Kishtagari, MBBS, MSCI7, Andrew Srisuwananukorn, MD8, Lorraine Pelosof, MD, PhD9, Steven Gore, MD10, Richard F. Little, MD11, Alexey V. Danilov, MD, PhD12, Theodore Karrison, PhD13, Olatoyosi Odenike, MD14
AFFILIATIONS
1 University of Chicago, Chicago, Illinois, United States
2 University of Chicago, Chicago, Illinois, United States
3 University of Chicago, Chicago, Illinois, United States
4 University of Kansas Medical Center, Kansas City, Kansas, United States
5 Cornell, New York City, New York, United States
6 University of Chicago, Chicago, Illinois, United States
7 Vanderbilt, Nashville, Tennessee, United States
8 The Ohio State University, Columbus, Ohio, United States
9 National Cancer Institute, Rockville, Maryland, United States
10 National Cancer Institute, Rockville, Maryland, United States
11 National Cancer Institute, Rockville, Maryland, United States
12 City of Hope, Duarte, California, United States
13 University of Chicago, Chicago, Illinois, United States
14 University of Chicago, Chicago, Illinois, United States
ABSTRACT
Background:
Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs) are hematopoietic stem cell malignancies that carry a risk of progression to an accelerated phase (AP) or blast phase (BP). In the current era of myeloid malignancy therapies, survival outcomes of MPN-AP/BP are poor with a median overall survival (OS) of less than 1 year (Patel et al, Blood Adv 2024). Pre-clinical studies have identified lysine-specific demethylase 1 (LSD1) inhibition as a therapeutic strategy in MPN-AP/BP; in addition, the oral LSD1 inhibitor iadademstat has been studied in combination with DNA methyltransferase inhibitor (DNMTi) therapy in de novo acute myeloid leukemia (AML) and demonstrated promising efficacy (Salamero et al, Lancet Haem 2024). These data have led to the development of a clinical trial investigating the oral DNMTi ASTX727 with or without iadademstat in patients (pts) with MPN-AP/BP (NCT06661915). This trial is being conducted via the National Cancer Institute (NCI) Experimental Therapeutics Clinical Trials Network (ETCTN).
Methods:
The study comprises a dose-escalation phase of iadademstat in combination with ASTX727 to identify a recommended phase 2 dose (R2PD), which will then be investigated in the randomized phase of this study. Relevant inclusion criteria are age ≥ 18 years, ECOG ≤3, no prior DNMTi treatment, and a diagnosis of MPN or myelodysplastic syndrome (MDS)/MPN in the accelerated or blast phase. Exclusion criteria of note include IDH1-mutated BP (since ivosidenib is an approved frontline therapy).
The dose escalation phase follows a 3+3 design. Cycles are 28 days. ASTX727 is 35mg-100mg on Days 1-5, while iadademstat dose level 1 (DL1) is 50mcg and DL2 is iadademstat 75mcg on Days 1-5, 8-12, 15-19, 22-26. The dose-limiting toxicity (DLT) window is Cycle 1. Responses are assessed using 2012 MPN-BP criteria (Mascarenhas et al, Leuk Res 2012). Data from a planned interim analysis upon enrollment of DL2, with a cut-off date of May 1, 2026, were analyzed.
Results:
Ten pts were treated at DL1 and 7 at DL2. The median age was 75.5 (range 64-84), 70% were female, and 70% were White.1 pt was Black, and 2 had undisclosed race. Eight pts had an antecedent MPN and 2 had MDS/MPN; 7 were in BP and 3 were in AP at time of enrollment. Eight pts had adverse-risk cytogenetics by European LeukemiaNet 2022 (ELN22) AML risk stratification. The most common molecular mutations were JAK2 (70%), TP53 (30%), K/NRAS (20%), and BCOR (20%). Seven pts had at least 1 adverse-risk mutation by ELN22 risk stratification.
No DLTs were observed in the study, including 3 pts - at DL1 and 6 pts at DL2. One pt enrolled at DL2 was unevaluable for DLT assessment due to progression of disease during Cycle 1. The most common Grade 3+ toxicities (≥22% incidence) were anemia (56%), neutropenic fever (56%), neutropenia without fever (33%), thrombocytopenia (22%), acute kidney injury (AKI) (22%), and sepsis (22%).
At DL1, 2 patients achieved acute leukemia response-partial (ALR-P) and 1 had stable disease as their best response at data cutoff. The best response for all 7 pts at DL2 was as follows: 3 with ALR-P, 2 with progressive disease, 1 with stable disease, and 1 was not evaluable for response. All three pts treated at DL1 are no longer on study (1 enrolled in hospice at the end of cycle 2, 1 due to progressive disease, 1 death due to disease). Of the 7 pts enrolled at DL2, 4 pts were still on study at the time of data cutoff. Three pts enrolled at DL2 are off study (2 due to progressive disease, 1 enrolled in hospice at the end of cycle 1).
Conclusions:
The combination of iadademstat and ASTX727 was well tolerated with No DLTs observed; common Grade 3+ toxicities include hematologic and infectious adverse events. Fifty percent of pts treated thus far have had an ALR-P as best response and we will monitor for deepening of response with subsequent cycles. LSD1 target engagement assays will be conducted on pts samples collected from pts treated on DL1 and DL2 to better characterize the appropriate dose of iadademstat. An amendment to investigate higher dose levels of iadademstat with ASTX727 in a continuation of the dose escalation phase has been approved. These additional dose levels will help to inform the selection of R2PD of iadademstat in combination with ASTX727 for the randomized portion of the study.
DISCLOSURES
Rafael Madero-Marroquin, MD: No relevant conflicts of interest to declare.